actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
== Deaths == 18 January – Sir David Cox, English statistician (b. 1924) 15 March – Eugene Parker, American solar and plasma physicist (b. 1927) 20 March – Wen Shengchang, Chinese oceanographer and member of the Chinese Academy of Sciences (b. 1921) 23 March – Arthur Riggs, American geneticist (b. 1939) 27 March – Martin Pope, American physical scientist (b. 1918) 27 March – James Vaupel, American demographer and aging researcher (b. 1945) 29 March – Paul Benioff, American physicist of quantum computing (b. 1930) 30 March – Kenneth Walters, British mathematician and rheologist (b. 1934) 1 April – Gerhard J. Woeginger, Austrian mathematician. 5 April – Sidney Altman, Canadian-American molecular biologist, Nobel Prize laureate (1989). 5 April – Bjarni Tryggvason, Icelandic-born Canadian astronaut (STS-85). 5 April – Eelco Visser, Dutch computer scientist. 5 April – Leslie Young, New Zealand economist. 1 May – Ray Freeman, British chemist. 1 May – Dominique Lecourt, French philosopher. 2 May – Joseph Raz, Israeli philosopher. 4 May – Amanda Claridge, Canadian archaeologist. 7 May – Sir Paul Mellars, British archaeologist. 8 May – Harry Dornbrand, American aerospace engineer. 8 May – Zhuang Qiaosheng, Chinese geneticist and wheat breeder, member of the Chinese Academy of Sciences. 9 May – John H. Coates, Australian mathematician. 14 May – Bernard Bigot, French physicist and civil servant, director general of ITER (b. 1950) 9 June – Gordon M. Shepherd, American neuroscientist. 26 July – James Lovelock, English environmentalist (Gaia hypothesis) and futurist (b.
== Finds == The body was identified as that of a person aged about 25 years, who had died in the first half of the 1st century BC. In addition to the sword in its bronze scabbard, a bronze mirror was found, and other grave goods included shield fittings, a sword belt ring, a brooch and a spiral ring (all of copper alloy), and a shattered tin object. All items were of classic celtic design. "There was also evidence for the grave having contained a sheepskin or fleece and woven textile incorporating goat and other animal hairs." The mirror and sword, after conservation, were given to the Isles of Scilly Museum, and as of 2023 are displayed in the museum's visitor centre in the town hall on St Mary's after the closure of the museum's building.
=== Muscle tone === Individuals with decreased muscle tone, increased soft tissue around the airway, and structural features that narrow the airway are at high risk for OSA. Men, whose anatomy is typified by increased mass in the torso and neck, are at increased risk of developing sleep apnea, especially in middle age and later. Typically, women experience this condition less frequently and to a lesser degree than do men, owing partially to physiology, but possibly also to differential levels of progesterone. Prevalence in post-menopausal women approaches that of men in the same age range. Women are at greater risk for developing OSA during pregnancy.
A soft-tissue sarcoma (STS) is a malignant tumor, a type of cancer, that develops in soft tissue. A soft-tissue sarcoma is often a painless mass that grows slowly over months or years. They may be superficial or deep-seated. Any such unexplained mass must be diagnosed by biopsy. Treatment may include surgery, radiotherapy, chemotherapy, and targeted drug therapy. Bone sarcomas are the other class of sarcomas. There are many different types, many of which are rarely found. The World Health Organization lists more than fifty subtypes.
CK is often determined routinely in a medical laboratory. It used to be determined specifically in patients with chest pain to recognize acute myocardial infarction, but this test has been largely replaced by troponin. Normal values at rest are usually between 60 and 400 IU/L, where one unit is enzyme activity, more specifically the amount of enzyme that will catalyze 1 μmol of substrate per minute under specified conditions (temperature, pH, substrate concentrations and activators.) This test is not specific for the type of CK that is elevated. Creatine kinase in the blood may be high in health and disease. Exercise increases the outflow of creatine kinase to the blood stream for up to a week, and this is the most common cause of high CK in blood. Furthermore, high CK in the blood may be related to high intracellular CK such as in persons of African descent. Finally, high CK in the blood may be an indication of damage to CK-rich tissue, such as in rhabdomyolysis, myocardial infarction, myositis and myocarditis. This means creatine kinase in blood may be elevated in a wide range of clinical conditions including the use of medication such as statins; endocrine disorders such as hypothyroidism; and skeletal muscle diseases and disorders including malignant hyperthermia, and neuroleptic malignant syndrome. Furthermore, the isoenzyme determination has in the past been used extensively as an indication for myocardial damage in heart attacks. Troponin measurement has largely replaced this in many hospitals, although some centers still rely on CK-MB.
Sources: en.wikipedia.org
On 6 December 2014, Pudzianowski defeated the olympic veteran Paweł Nastula via unanimous decision on KSW 29's co-main event. It was his third win in a row. Pudzianowski next fought Rolles Gracie Jr. in KSW 31, on 23 May 2015 in Gdańsk, Poland. He defeated Gracie Jr. via knockout in the 1st round, winning the Knockout of the Night bonus award with the performance. At KSW 32 on 31 October 2015, Pudzianowski lost to Peter Graham via TKO in the second round. Then on 27 May 2016 at KSW 35 against Marcin Różalski, he lost also in the second round this time by guillotine choke. In his next fight in KSW 37 on 3 December 2016 Pudzianowski defeated Paweł Mikołajuw with TKO in the first round. On 27 May 2017 at KSW 39 Pudzianowski defeated Tyberiusz Kowalczyk via submission to elbow strike in the second round. Pudzianowski was expected to face James McSweeney at KSW 40 on 22 October 2017. However, after McSweeney was medically cleared, he eventually faced Jay Silva and won by majority decision. Mariusz faced Karol Bedorf on 9 June 2018 at KSW 44: The Game. He lost the bout via first round kimura. Mariusz faced Szymon Kołecki in a heavyweight bout at KSW 47 on 23 March 2019. Pudzianowski lost the fight after suffering a leg injury in the first round.
Myxedema (British English: myxoedema) is a term used synonymously with severe hypothyroidism, but also to describe a dermatological change that can occur in hypothyroidism and (rare) paradoxical cases of hyperthyroidism. In this latter sense, myxedema refers to deposition of glycosaminoglycans in the dermis, which results in swelling of the affected area. One manifestation of myxedema occurring in the lower limb is pretibial myxedema, a hallmark of Graves' disease, an autoimmune form of hyperthyroidism. Myxedema can also occur in Hashimoto thyroiditis and other long-standing forms of hypothyroidism.
However, Kc will vary with ionic strength. If it is measured at a series of different ionic strengths, the value can be extrapolated to zero ionic strength. The concentration quotient obtained in this manner is known, paradoxically, as a thermodynamic equilibrium constant. Before using a published value of an equilibrium constant in conditions of ionic strength different from the conditions used in its determination, the value should be adjusted.
8 June Following a meeting at Midway Island between Nixon and Thiệu, Nixon announced that 25,000 American troops would be withdrawn from South Vietnam by the end of August, starting the process of Vietnamization. First Lieutenant Sharon Ann Lane, an army nurse at the 312th Evacuation Hospital at Chu Lai Base Area, was killed in a PAVN rocket attack. She was the only U.S. servicewoman killed by hostile fire during the war. The PAVN 90th Regiment attacked the night defensive position of the 1st Battalion, 5th Marines in the "Arizona Territory" northeast of An Hoa Combat Base. The Marines repelled the assault and pursued the PAVN throughout the day resulting in more than 185 PAVN killed.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.